Traws Pharma gets Nasdaq minimum bid price notice

Rhea-AI Filing Summary

Traws Pharma, Inc. reported that on July 29, 2026 it received a notification letter from the Nasdaq Listing Qualifications Department stating that its common stock is not in compliance with the Nasdaq Capital Market minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price has been below $1.00 per share for at least 30 consecutive business days. The notice does not immediately affect the company’s Nasdaq listing.

Traws Pharma has 180 calendar days, until January 25, 2027, to regain compliance, which requires a closing bid price at or above $1.00 per share for at least 10 consecutive business days, a period Nasdaq may extend to up to 20 days. If compliance is not regained, Nasdaq may grant a second 180‑day grace period if other listing standards are met and the company plans to cure the deficiency. Otherwise, the stock may be subject to delisting, which the company could appeal. Traws Pharma states it will monitor its bid price and consider options, but there is no assurance of regaining compliance.

Positive

• None.

Negative

• Nasdaq minimum bid price deficiency increases the risk of Traws Pharma’s common stock being delisted if it cannot restore a bid of at least $1.00 within the allowed compliance periods.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Minimum bid price requirement: $1.00 per share Non-compliance trigger period: 30 consecutive business days Initial compliance period: 180 calendar days +2 more

5 metrics

Minimum bid price requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) threshold for continued listing

Non-compliance trigger period 30 consecutive business days Closing bid below $1.00 for at least this period

Initial compliance period 180 calendar days From July 29, 2026 to January 25, 2027 to regain compliance

Price cure window 10 consecutive business days Bid must close at or above $1.00 for at least this period

Potential second grace period 180 calendar days May be granted if other listing standards are met

Key Terms

Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), Nasdaq Capital Market, Nasdaq Listing Qualifications Department, +1 more

5 terms

Minimum Bid Price Requirement regulatory

"not in compliance with the minimum bid price requirement for continued listing"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Nasdaq Listing Rule 5550(a)(2) regulatory

"as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”)"

Nasdaq Capital Market regulatory

"continued listing on The Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

Nasdaq Listing Qualifications Department regulatory

"received a notification letter from the Nasdaq Listing Qualifications Department"

The Nasdaq Listing Qualifications Department is the team at the Nasdaq stock market that monitors whether listed companies meet the exchange’s rules for things like minimum share price, market value, timely financial reporting and governance. Its role matters to investors because its notices, warnings or enforcement actions—ranging from reminders to suspension or delisting—can sharply affect a stock’s trading, liquidity and perceived risk; think of it as the referee enforcing the marketplace’s entry and conduct rules.

market value of publicly held shares financial

"meets the continued listing requirement for market value of publicly held shares"

The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq notice did Traws Pharma (TRAW) receive on July 29, 2026?

Nasdaq notified Traws Pharma that its common stock no longer meets the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), after trading below $1.00 for at least 30 consecutive business days, triggering a formal deficiency period.

How long does Traws Pharma (TRAW) have to regain Nasdaq bid-price compliance?

Traws Pharma has 180 calendar days, until January 25, 2027, to regain compliance. It must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, subject to Nasdaq’s discretion to extend that period.

What happens if Traws Pharma (TRAW) restores its bid to $1.00 on Nasdaq?

If Traws Pharma’s closing bid is at or above $1.00 for at least 10 consecutive business days before January 25, 2027, Nasdaq will issue written confirmation that the company has regained compliance with the minimum bid price requirement and the matter will be resolved.

Can Traws Pharma (TRAW) receive a second grace period from Nasdaq?

If Traws Pharma fails to regain compliance by January 25, 2027, Nasdaq may grant a second 180‑day grace period, provided the company meets other initial Nasdaq Capital Market listing standards and informs Nasdaq of its intent to cure the bid‑price deficiency.

What are the delisting risks for Traws Pharma (TRAW) after this Nasdaq notice?

If Traws Pharma does not regain or maintain compliance within the allowed periods, Nasdaq may delist its common stock. The company would receive delisting notice and could appeal to a Nasdaq hearings panel, but there is no assurance an appeal would succeed.

Does the Nasdaq bid-price notice immediately affect trading in Traws Pharma (TRAW) stock?

The notice has no immediate effect on Traws Pharma’s Nasdaq Capital Market listing. Its common stock continues to trade as before while the company works within the 180‑day compliance period to address the minimum bid price deficiency.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:16 PM Accepted by SEC EDGAR 07/31/2026 - 04:15 PM Learn about SEC filing dates

false 0001130598 0001130598 2026-07-29 2026-07-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 29, 2026

Traws Pharma, Inc.

(Exact name of Registrant as specified in its charter)

Delaware		001-36020		22-3627252
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

12 Penns Trail

Newtown, PA 18940

(267) 759-3680

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $.01 per share	TRAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 29, 2026, Traws Pharma, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for at least 30 consecutive business days, the Company is not currently in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

The notification has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market, and, therefore, the Company’s listing remains fully effective.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from July 29, 2026 or until January 25, 2027, to regain compliance with the Minimum Bid Price Requirement. If at any time before January 25, 2027, the closing bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days (which may be extended to be a period of up to 20 consecutive business days at the discretion of Nasdaq), Nasdaq will provide written notification that the Company has regained compliance with the Minimum Bid Price Requirement, and the matter would be resolved. If the Company does not regain compliance during the compliance period ending on January 25, 2027, then Nasdaq may grant the Company a second 180 calendar day grace period to regain compliance, provided the Company (i) meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and (ii) the Company notifies Nasdaq of its intent to cure the deficiency during the second compliance period.

The Company intends to continue actively monitoring the closing bid price for the Company’s common stock between now and January 25, 2027, and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the 180-day compliance period, secure a second period of 180 days to regain compliance, or maintain compliance with the other Nasdaq listing requirements. 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		TRAWS PHARMA, INC.
Date: July 31, 2026	By:	/s/ Charles Parker
		Name:	Charles Parker
		Title:	Chief Financial Officer

3

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB